期刊
CANCER TREATMENT REVIEWS
卷 39, 期 7, 页码 802-811出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.ctrv.2013.02.002
关键词
Survivin; BIRC5; YM155; LY2181308; SPC3042
类别
资金
- National Science council, Taiwan, ROC [NSC100-2314-B-006-075, NSC101-2320-B-006-041]
- National Health Research Institutes, Taiwan, ROC [NHRI-EX102-10237SC]
- Aim for the Top University Project (National Cheng Kung University, Taiwan, ROC)
- National Cheng Kung University Hospital, Taiwan, ROC [NCKUH-10007012]
Since the discovery of survivin (BIRC5) as a cancer-related molecule by Grazia Ambrosini and Dario C. Altieri at 1997, our knowledge related to the function of this molecule has been extended from simple apoptosis inhibition to complicated, interlinked processes that involve interference of mitosis, apoptosis, autophagy, and even DNA repair recently. However, despite the growing amount of knowledge related to survivin in the last ten years, the development of survivin inhibitors or survivin-related molecular therapies is surprisingly and relatively slow as compared to other therapeutic inhibitors for cancer treatment. Here, the molecular functions of survivin and the progress of development of survivin-targeting therapies are discussed in detail. Functional differences between different survivin-specific inhibitors are discussed from both structural and biochemical point of views. This review also reveals different challenges that scientists are currently facing in the development of survivin inhibitors for clinical application. Finally, future directions for the development of survivin-targeted therapies are discussed in this review. (C) 2013 Elsevier Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据